Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.64 |
| ▸ | GLA | P06280 | 3/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | ATM | Q13315 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | CASP1 | P29466 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | CASP7 | P55210 | 1/20 | 0.58 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.58 |
| ▸ | RCE1 | Q9Y256 | 1/20 | 0.58 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.58 |
| ▸ | IKBKB | O14920 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4547547 | 0.88 | ALDH1A1 (0.64) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL4654000 | 0.84 | BCKDK (0.50) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL8435973 | 0.84 | KDM4E (0.66) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL15766305 | 0.83 | BCKDK (0.53) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL25208220 | 0.82 | BCKDK (0.49) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL8142110 | 0.82 | KDM4E (0.64) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL693146 | 0.82 | BCKDK (0.68) | ALDH1A1HPGDKDM4EMAPTGAA | |
| SCHEMBL31015908 | 0.82 | BCKDK (0.49) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL31015992 | 0.82 | BCKDK (0.49) | ALDH1A1HPGDHSD17B10KDM4EGLA | |
| SCHEMBL25211925 | 0.82 | BCKDK (0.49) | ALDH1A1HPGDHSD17B10KDM4EGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | PFIZER INC. (US) | 2025-11-11 | — | — | US | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| CN-118451066-A | 3-Phenyl-1-benzothiophene-2-carboxylic acid derivatives as inhibitors of branched alpha ketoacid dehydrogenase kinase for the treatment of diabetes, kidney disease, NASH and heart failure | 辉瑞大药厂 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023100061-A1 | 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE | PFIZER INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| WO-2023100061-A1 | 3-PHENYL-1-BENZOTHIOPHENE-2-CARBOXYLIC ACID DERIVATIVES AS BRANCHED-CHAIN ALPHA KETO ACID DEHYDROGENASE KINASE INHIBITORS FOR THE TREATMENT OF DIABETES, KIDNEY DISEASES, NASH AND HEART FAILURE | PFIZER INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2023-06-01 | — | — | US | disclosed |
| US-7772252-B2 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. (US) | 2010-08-10 | — | — | US | disclosed |
| EP-1935887-B1 | Heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMA INC (US) | 2010-01-13 | — | — | EP | disclosed |
| US-20030229066-A1 | Novel heterocyclic urea derivatives and their use as dopamine D3 receptor ligands | AVENTIS PHARMACEUTICALS INC. | 2003-12-11 | — | — | US | disclosed |
| EP-1361875-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| EP-1362039-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | Aventis Pharmaceuticals, Inc. (US) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002066468-A2 | HETEROCYCLIC UREA DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066469-A2 | NOVEL HETEROCYCLIC AMIDE DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002066446-A1 | HETEROCYCLIC SUBSTITUTED CARBONYL DERIVATIVES AND THEIR USE AS DOPAMINE D3 RECEPTOR LIGANDS | AVENTIS PHARMACEUTICALS INC. (US) | 2002-08-29 | — | — | WO | disclosed |
| EP-0511610-B1 | Benzisothiazole- and benzisoxazole-3-carboxamides, a process for their preparation and their use as antipsychotic medicaments | HOECHST ROUSSEL PHARMA (US) | 1996-09-11 | — | — | EP | disclosed |
| US-5225412-A | Antipsychotic | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1993-07-06 | — | — | US | disclosed |
| EP-0511610-A1 | Benzisothiazole- and benzisoxazole-3-carboxamides, a process for their preparation and their use as antipsychotic medicaments | HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED (US) | 1992-11-04 | — | — | EP | disclosed |
| US-5143923-A | Psychological disorders | HOECHST-ROUSSEL PHARMACEUTICALS INC. (US) | 1992-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12466803-B2 | BCKDK inhibitors and/or degraders | BCKDK, KHK, PDK4 | ALDH1A1 468/4885HPGD 465/4885HSD17B10 32/4885 |
| US-20230167080-A1 | BCKDK INHIBITORS AND/OR DEGRADERS | BCKDK, KHK, PDK4 | ALDH1A1 468/4885HPGD 465/4885HSD17B10 32/4885 |
| US-20030229066-A1 | Novel heterocyclic urea derivatives and their use as dopamine D3 receptor ligands | DRD3, DRD2, DRD1 | ALDH1A1 1973/4885HPGD 2084/4885HSD17B10 3490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.